October 7, 2020

Lilly Provides Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Press release, not peer-reviewed] A combination of two monoclonal antibodies showed evidence of efficacy for treatment of mild-to-moderate COVID-19. A randomized, double-blind, placebo-controlled Phase 2 trial (BLAZE-1 trial) showed that combination therapy with two of Lilly’s SARS-CoV-2 neutralizing antibodies (LY-CoV555 and LY-CoV016) administered to patients with mild-to-moderate COVID-19 (112 received antibody, 156 received placebo) reduced viral load, symptoms, and COVID-related hospitalization and emergency room visits. The combination therapy has been generally well tolerated with no drug-related serious adverse events.

Lilly. (Oct 7, 2020). Lilly Provides Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs. https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2